ABSTRACT
Background: Persons with type 2 diabetes mellitus (T2DM) are at high?risk for COVID?19 infection and are a priority group for vaccination. Objectives: The objective of this study is to estimate the seroconversion and determine the side effects after COVID?19 vaccination among persons with T2DM in urban, rural, and tribal areas in Kerala. Methods: A cross-sectional study was conducted in urban, rural, and tribal field practice areas of a medical college in Central Kerala, among 396 persons with T2DM. The participants were selected by simple random sampling from the 200–250 diabetic patients visiting each health center. Qualitative and quantitative estimation of antibodies were done by WANTAI Ab enzyme?linked immunosorbent assay kit and Abbott SARS COV?2 IgG Quantitative assay, respectively. Results: The mean age of the respondents was 59.40 ± 12.25 years. A majority (65.5%) had received both doses of vaccine. About half (51.5%) experienced side effects after vaccination. Antibodies (IgG or IgM) were detected in 93.2% (95% confidence interval [CI] 90.2, 95.5) of participants. Those with a duration of diabetes ?5 years, with a single dose of vaccine, were five times (adjusted odds ratio [aOR] – 5.23,95% CI 1.86, 14.66) and four times (aOR – 4.11, 95% CI 1.66, 10.13) more likely, respectively, to be seronegative. Those who took medication for diabetes were protected against a no antibody (aOR – 0.05, 95% CI 0.02, 0.148) response. The median antibody titer in a subset (150) of participants was 365.2 (90–1587) AU/ml. Past COVID infection was an independent determinant of high IgG titers (aOR – 4.95, 95% CI 1.50, 16.36). Conclusion: Reinforcing the importance of vaccination particularly among those with longer duration of diabetes is imperative.
ABSTRACT
Background: COVID vaccines have been rolled out all over the world after emergency use authorization in the prevailing pandemic situation. However, hesitancy about its safety and efficacy exists among beneficiaries. Vaccine hesitancy can be a barrier to adequate immunization coverage. Aims and Objectives: This qualitative study was undertaken among health care workers in the rural field practice area of a tertiary care hospital, to find out their perceptions about COVID vaccines, and reasons behind hesitancy toward the same. Materials and Methods: Six focused group discussions (FGD) were held with the help of moderator. Each FGD had five members, so 30 members were included in the study. Health care workers included doctors, nurses, ANM/ASHAs, and other health care workers. Results: There were 17 males and 13 females. Doctors had a positive attitude toward vaccination, but other health care workers had mixed perception regarding vaccination. Most grass root level workers were sceptical about the efficacy of the vaccine. Conclusion: Mostly positive attitude toward COVID vaccines was observed in the present study. Hesitancy toward vaccines was observed in some health care workers, and it likely rooted from their inadequate knowledge about the vaccine.
ABSTRACT
Background: Severe acute respiratory syndrome (SARS) coronavirus-2-novel coronavirus termed as COVID 19 is a major outbreak which was deleterious globally created a rapid cases of pulmonary infectious disease that caused the SARS. Building up confidence in vaccination depends on the interaction between public and doctors. Attitude toward usage of vaccination by healthcare workers (HCWs) is a major factor that is associated with general public acceptance of vaccination, fidelity to schedules, and devoid of hesitation/aversion. In addition, vaccinated HCWs also have a perceptible effect of decisiveness in general public to take a vaccine. Aims and Objectives: To understand the knowledge, attitude and practices on COVID vaccine among HCWs. Materials and Methods: This is a hospital-based, observational cross-sectional study done in Hassan Institute of Medical Sciences, Teaching hospital, Hassan. A sample of 340 HCWs who have been vaccinated 1st dose of inactivated COVID Vaccine was taken up for the study. A predesigned questionnaire was prepared and given to all the HCWs in the observation period of 30 min after vaccination. The questionnaire had 13 questions, and the data were collected and analyzed. Data were analyzed by descriptive statistical analysis. Results: This study was done in a district hospital, Hassan, Karnataka with a sample size of 340 HCWs participated in the study and completed the study questionnaire, out of which 146 men (43.4%) and 190 women (56.54%). Willingness to take the vaccine is 96%. 93.4% of HCWs encourage others to take vaccine. Our institution arranged a adverse events following immunization reporting and monitoring team management and 93.9% of the HCWs knew where to report if any adverse events occur in the observation period of 30 min after vaccination and also after going back to their respective homes through a telephone number and also this will help knowing the and acceptability of the vaccines. Conclusion: HCWs play an influential role in general public vaccination program. The information from this study will help to gain more knowledge and also allow the general public to future vaccination acceptability. The approach of HCWs might help in creating awareness and preventing false information about COVID vaccine among general public.
ABSTRACT
Background & objectives: The COVID-19 pandemic has caused significant global morbidity and mortality. As the vaccination was rolled out with prioritization on healthcare workers (HCWs), it was desirable to generate evidence on effectiveness of vaccine in prevailing real-life situation for policy planning. The objective of the study was to evaluate the safety, effectiveness and immunogenicity of COVID-19 vaccination among HCWs in a tertiary care hospital. Methods: This prospective observational study was undertaken on the safety, immunogenicity and effectiveness of the ChAdOx1 nCoV- 19 coronavirus vaccine (Recombinant) during the national vaccine roll out in January-March 2021, in a tertiary care hospital, New Delhi, India. Results: The vaccine was found to be safe, with local pain, fever and headache as the most common adverse events of milder nature which generally lasted for two days. The adverse events following vaccination were lower in the second dose as compared to the first dose. The vaccine was immunogenic, with seropositivity, which was 51 per cent before vaccination, increasing to 77 per cent after single dose and 98 per cent after two doses. Subgroup analysis indicated that those with the past history of COVID-19 attained seropositivity of 98 per cent even with single dose. The incidence of reverse transcription (RT)-PCR positive COVID-19 was significantly lower among vaccinated (11.7%) as compared to unvaccinated (22.2%). Seven cases of moderate COVID-19 needing hospitalization were seen in the unvaccinated and only one such in the vaccinated group. The difference was significant between the fully vaccinated (10.8%) and the partially vaccinated (12.7%). The hazard of COVID-19 infection was higher among male, age >50 yr and clinical role in the hospital. After adjustment for these factors, the hazard of COVID-19 infection among unvaccinated was 2.09 as compared to fully vaccinated. Vaccine effectiveness was 52.2 per cent in HCWs. Interpretation & conclusions: ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) was safe, immunogenic as well as showed effectiveness against the COVID-19 disease (CTRI/2021/01/030582).
ABSTRACT
The coronavirus disease 2019 (COVID-19) is a contagious viral infection of the respiratory system caused by SARS-coronavirus-2 (SARS-CoV-2). The outbreak of the disease was first reported in Wuhan, China in December 2019. The spread of COVID-19 is continuous and was declared a pandemic disease by the World Health Organization (WHO) on 11 March, 2020. As of 20 May 2020, more than 4.7 million people have contracted the disease and 318,789 people have died.Vaccines save millions of lives each year. The development of safe and effective COVID-19 vaccines is a huge step forward in our global effort to end the pandemic and to get back to doing more of the things we enjoy with the people we love
ABSTRACT
@#This case series described four healthcare workers with exposure to patients and co-workers, who were potential or confirmed cases of COVID-19. They had negative nasopharyngeal swab reverse transcriptase polymerase chain reaction (RT-PCR) tests at different time points and had zero IgG antibodies on VITROS Anti-SARS-CoV-2 IgG Antibody test prior to CoronaVac inoculation on March 1, 2021. The levels of antibody titers, which showed increasing then declining trends of immunoglobulins, were measured at different time points. Although the antibody levels are not proof of immunity against SARS-CoV-2 and the protective quantity is yet to be determined, the titers are evidence that vaccines do elicit an immune response and may have a role in the fight against infection